دورية أكاديمية
أعرض في EDS

Antibody response to a new member of the DBL family (EBP2) after a brief Plasmodium vivax exposure.

التفاصيل البيبلوغرافية
العنوان: Antibody response to a new member of the DBL family (EBP2) after a brief Plasmodium vivax exposure.
المؤلفون: Lima BAS; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Fernandes GM; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Torres LM; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Pires CV; Center for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, Florida, United States of America., Alves JRS; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Moreira-Nascimento SL; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Nascimento MFA; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Afonso SL; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Costa HL; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Cerávolo IP; Laboratório de Imunopatologia, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Sousa TN; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Soares IS; Departamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, Brazil., Ntumngia FB; Center for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, Florida, United States of America., Adams JH; Center for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, Florida, United States of America., Carvalho LH; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil., Kano FS; Biologia Molecular e Imunologia da Malária, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Minas Gerais, Brazil.
المصدر: PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2022 Jun 17; Vol. 16 (6), pp. e0010493. Date of Electronic Publication: 2022 Jun 17 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Malaria* , Malaria, Vivax*/parasitology, Antibodies, Protozoan ; Antibody Formation ; Antigens, Protozoan/genetics ; Cross-Sectional Studies ; Humans ; Immunoglobulin G ; Immunoglobulin M ; Plasmodium vivax/genetics ; Protozoan Proteins/genetics ; Receptors, Cell Surface/genetics
مستخلص: Plasmodium vivax blood-stage invasion into reticulocyte is critical for parasite development. Thus, validation of novel parasite invasion ligands is essential for malaria vaccine development. Recently, we demonstrated that EBP2, a Duffy binding protein (DBP) paralog, is antigenically distinct from DBP and could not be functionally inhibited by anti-DBP antibodies. Here, we took advantage of a small outbreak of P.vivax malaria, located in a non-malarious area of Brazil, to investigate for the first time IgM/IgG antibodies against EBP2 and DEKnull-2 (an engineering DBPII vaccine) among individuals who had their first and brief exposure to P.vivax (16 cases and 22 non-cases). Our experimental approach included 4 cross sectional surveys at 3-month interval (12-month follow-up). The results demonstrated that while a brief initial P.vivax infection was not efficient to induce IgM/ IgG antibodies to either EBP2 or DEKnull-2, IgG antibodies against DEKnull-2 (but not EBP2) were boosted by recurrent blood-stage infections following treatment. Of interest, in most recurrent P. vivax infections (4 out of 6 patients) DEKnull-2 IgG antibodies were sustained for 6 to 12 months. Polymorphisms in the ebp2 gene does not seem to explain EBP2 low immunogenicity as the ebp2 allele associated with the P.vivax outbreak presented high identity to the original EBP2 isolate used as recombinant protein. Although EBP2 antibodies were barely detectable after a primary episode of P.vivax infection, EBP2 was highly recognized by serum IgG from long-term malaria-exposed Amazonians (range from 35 to 92% according to previous malaria episodes). Taken together, the results showed that individuals with a single and brief exposure to P.vivax infection develop very low anti-EBP2 antibodies, which tend to increase after long-term malaria exposure. Finally, the findings highlighted the potential of DEKnull-2 as a vaccine candidate, as in non-immune individuals anti-DEKnull-2 IgG antibodies were boosted even after a brief exposure to P.vivax blood stages.
Competing Interests: The authors have declared that no competing interests exist.
References: Sci Rep. 2017 Oct 23;7(1):13779. (PMID: 29062081)
mBio. 2016 Aug 23;7(4):. (PMID: 27555313)
Malar J. 2010 Nov 22;9:334. (PMID: 21092207)
Infect Immun. 2009 Sep;77(9):4009-17. (PMID: 19564376)
Cell. 1990 Oct 5;63(1):141-53. (PMID: 2170017)
Malar J. 2003 Nov 14;2(1):39. (PMID: 14617378)
Science. 1975 Feb 28;187(4178):748-50. (PMID: 803712)
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8363-8. (PMID: 18523022)
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7085-9. (PMID: 1496004)
PLoS Med. 2008 Jun 17;5(6):e127. (PMID: 18563961)
J Infect Dis. 2007 Apr 1;195(7):927-33. (PMID: 17330781)
Am J Trop Med Hyg. 2010 Feb;82(2):185-93. (PMID: 20133990)
Nature. 2006 Feb 9;439(7077):741-4. (PMID: 16372020)
PLoS One. 2014 Apr 07;9(4):e93782. (PMID: 24710306)
PLoS Med. 2008 Jun 17;5(6):e128. (PMID: 18563962)
Microorganisms. 2020 Dec 23;9(1):. (PMID: 33374596)
Elife. 2017 Sep 26;6:. (PMID: 28949293)
Clin Exp Immunol. 2009 Jun;156(3):502-10. (PMID: 19438604)
PLoS Negl Trop Dis. 2019 Feb 15;13(2):e0006987. (PMID: 30768655)
Mol Biochem Parasitol. 2003 Apr 3;127(2):121-32. (PMID: 12672521)
PLoS Negl Trop Dis. 2016 Dec 13;10(12):e0005177. (PMID: 27959918)
PLoS Med. 2007 Dec;4(12):e350. (PMID: 18092888)
mBio. 2018 Jan 23;9(1):. (PMID: 29362233)
Cell Host Microbe. 2017 Aug 9;22(2):232-245. (PMID: 28799908)
PLoS Negl Trop Dis. 2020 Jul 9;14(7):e0008202. (PMID: 32645098)
PLoS One. 2020 May 7;15(5):e0232786. (PMID: 32379804)
Exp Parasitol. 1989 Nov;69(4):340-50. (PMID: 2680568)
Cell. 2006 Feb 24;124(4):755-66. (PMID: 16497586)
Am J Prev Med. 2015 Dec;49(6 Suppl 4):S319-33. (PMID: 26590432)
Trends Parasitol. 2016 Apr;32(4):284-295. (PMID: 26778295)
J Infect Dis. 2016 Nov 15;214(10):1539-1546. (PMID: 27578850)
Infect Immun. 1994 Dec;62(12):5581-6. (PMID: 7960140)
PLoS Negl Trop Dis. 2013 Dec 05;7(12):e2569. (PMID: 24340114)
Curr Opin Microbiol. 2018 Dec;46:109-115. (PMID: 30366310)
Vaccine. 2015 Dec 22;33(52):7489-95. (PMID: 26428453)
Sci Transl Med. 2019 Jan 9;11(474):. (PMID: 30626712)
Clin Vaccine Immunol. 2012 Jan;19(1):30-6. (PMID: 22116684)
Trends Parasitol. 2009 May;25(5):220-7. (PMID: 19349210)
Trop Med Int Health. 2012 Aug;17(8):989-1000. (PMID: 22643072)
Infect Immun. 2000 Jun;68(6):3164-71. (PMID: 10816459)
Int J Parasitol Drugs Drug Resist. 2021 Apr;15:9-24. (PMID: 33360105)
Scand J Immunol. 2008 Mar;67(3):270-8. (PMID: 18226014)
معلومات مُعتمدة: R01 AI064478 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Antibodies, Protozoan)
0 (Antigens, Protozoan)
0 (Immunoglobulin G)
0 (Immunoglobulin M)
0 (Protozoan Proteins)
0 (Receptors, Cell Surface)
تواريخ الأحداث: Date Created: 20220617 Date Completed: 20220621 Latest Revision: 20230217
رمز التحديث: 20230217
مُعرف محوري في PubMed: PMC9205486
DOI: 10.1371/journal.pntd.0010493
PMID: 35714097
قاعدة البيانات: MEDLINE
الوصف
تدمد:1935-2735
DOI:10.1371/journal.pntd.0010493